Qualigen Therapeutics Partners with TD2 for Phase 1 Clinical Development of QN-302 for the Treatment of Advanced or Metastatic Solid Tumors

Stock Information for Qualigen Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Qualigen Therapeutics Inc.

Qualigen Therapeutics Announces Regained Compliance with Nasdaq's Minimum Bid Price Requirement and the Equity Requirement
Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares
Shares Expected to Begin Trading on Split-Adjusted Basis on November 5, 2024
Qualigen Therapeutics, Inc. Announces management changes.
Qualigen Therapeutics, Inc. Received Extension from Nasdaq Hearings Panel
Univest Securities, LLC Announces Closing of $3.46 Million Registered Direct Offering for its Client Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
Qualigen Therapeutics, Inc. Announces Closing of $3.47 Million Public Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.